Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 418

Similar articles for PubMed (Select 23524209)

1.

Renal impairment and ischemic stroke risk assessment in patients with atrial fibrillation: the Loire Valley Atrial Fibrillation Project.

Banerjee A, Fauchier L, Vourc'h P, Andres CR, Taillandier S, Halimi JM, Lip GY.

J Am Coll Cardiol. 2013 May 21;61(20):2079-87. doi: 10.1016/j.jacc.2013.02.035. Epub 2013 Mar 21.

2.

The HAS-BLED score has better prediction accuracy for major bleeding than CHADS2 or CHA2DS2-VASc scores in anticoagulated patients with atrial fibrillation.

Roldán V, Marín F, Manzano-Fernández S, Gallego P, Vílchez JA, Valdés M, Vicente V, Lip GY.

J Am Coll Cardiol. 2013 Dec 10;62(23):2199-204. doi: 10.1016/j.jacc.2013.08.1623. Epub 2013 Sep 18.

3.

Risk factors for stroke and thromboembolism in relation to age among patients with atrial fibrillation: the Loire Valley Atrial Fibrillation Project.

Olesen JB, Fauchier L, Lane DA, Taillandier S, Lip GY.

Chest. 2012 Jan;141(1):147-53. doi: 10.1378/chest.11-0862. Epub 2011 Jun 16.

PMID:
21680645
4.

Renal dysfunction as a predictor of stroke and systemic embolism in patients with nonvalvular atrial fibrillation: validation of the R(2)CHADS(2) index in the ROCKET AF (Rivaroxaban Once-daily, oral, direct factor Xa inhibition Compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation) and ATRIA (AnTicoagulation and Risk factors In Atrial fibrillation) study cohorts.

Piccini JP, Stevens SR, Chang Y, Singer DE, Lokhnygina Y, Go AS, Patel MR, Mahaffey KW, Halperin JL, Breithardt G, Hankey GJ, Hacke W, Becker RC, Nessel CC, Fox KA, Califf RM; ROCKET AF Steering Committee and Investigators.

Circulation. 2013 Jan 15;127(2):224-32. doi: 10.1161/CIRCULATIONAHA.112.107128. Epub 2012 Dec 3.

5.

Reliable identification of "truly low" thromboembolic risk in patients initially diagnosed with "lone" atrial fibrillation: the Belgrade atrial fibrillation study.

Potpara TS, Polovina MM, Licina MM, Marinkovic JM, Prostran MS, Lip GY.

Circ Arrhythm Electrophysiol. 2012 Apr;5(2):319-26. doi: 10.1161/CIRCEP.111.966713. Epub 2012 Feb 8.

6.

Pattern of atrial fibrillation and risk of outcomes: the Loire Valley Atrial Fibrillation Project.

Banerjee A, Taillandier S, Olesen JB, Lane DA, Lallemand B, Lip GY, Fauchier L.

Int J Cardiol. 2013 Sep 10;167(6):2682-7. doi: 10.1016/j.ijcard.2012.06.118. Epub 2012 Jul 15.

PMID:
22795403
7.

Net clinical benefit of antithrombotic therapy in patients with atrial fibrillation and chronic kidney disease: a nationwide observational cohort study.

Bonde AN, Lip GY, Kamper AL, Hansen PR, Lamberts M, Hommel K, Hansen ML, Gislason GH, Torp-Pedersen C, Olesen JB.

J Am Coll Cardiol. 2014 Dec 16;64(23):2471-82. doi: 10.1016/j.jacc.2014.09.051.

PMID:
25500231
8.

Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation.

Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ.

Chest. 2010 Feb;137(2):263-72. doi: 10.1378/chest.09-1584. Epub 2009 Sep 17.

PMID:
19762550
9.

A prospective study of estimated glomerular filtration rate and outcomes in patients with atrial fibrillation: the Loire Valley Atrial Fibrillation Project.

Banerjee A, Fauchier L, Vourc'h P, Andres CR, Taillandier S, Halimi JM, Lip GY.

Chest. 2014 Jun;145(6):1370-82. doi: 10.1378/chest.13-2103.

PMID:
24356875
10.

Renal dysfunction, stroke risk scores (CHADS2, CHA2DS2-VASc, and R2CHADS2), and the risk of thromboembolic events after catheter ablation of atrial fibrillation: the Leipzig Heart Center AF Ablation Registry.

Kornej J, Hindricks G, Kosiuk J, Arya A, Sommer P, Husser D, Rolf S, Richter S, Piorkowski C, Gaspar T, Lip GY, Bollmann A.

Circ Arrhythm Electrophysiol. 2013 Oct;6(5):868-74. doi: 10.1161/CIRCEP.113.000869. Epub 2013 Sep 18.

11.

Vascular disease and stroke risk in atrial fibrillation: a nationwide cohort study.

Olesen JB, Lip GY, Lane DA, Køber L, Hansen ML, Karasoy D, Hansen CM, Gislason GH, Torp-Pedersen C.

Am J Med. 2012 Aug;125(8):826.e13-23. doi: 10.1016/j.amjmed.2011.11.024. Epub 2012 May 10.

PMID:
22579139
12.

Evaluation of risk stratification schemes for ischaemic stroke and bleeding in 182 678 patients with atrial fibrillation: the Swedish Atrial Fibrillation cohort study.

Friberg L, Rosenqvist M, Lip GY.

Eur Heart J. 2012 Jun;33(12):1500-10. doi: 10.1093/eurheartj/ehr488. Epub 2012 Jan 13.

13.

The value of the CHA2DS2-VASc score for refining stroke risk stratification in patients with atrial fibrillation with a CHADS2 score 0-1: a nationwide cohort study.

Olesen JB, Torp-Pedersen C, Hansen ML, Lip GY.

Thromb Haemost. 2012 Jun;107(6):1172-9. doi: 10.1160/TH12-03-0175. Epub 2012 Apr 3.

PMID:
22473219
14.

Comparison between CHADS2 and CHA2 DS2 -VASc score in a stroke cohort with atrial fibrillation.

Giralt-Steinhauer E, Cuadrado-Godia E, Ois A, Jiménez-Conde J, Rodríguez-Campello Á, Soriano C, Roquer J.

Eur J Neurol. 2013 Apr;20(4):623-8. doi: 10.1111/j.1468-1331.2012.03807.x. Epub 2012 Jul 27.

PMID:
22834861
15.

Chronic kidney disease and CHADS(2) score independently predict cardiovascular events and mortality in patients with nonvalvular atrial fibrillation.

Nakagawa K, Hirai T, Takashima S, Fukuda N, Ohara K, Sasahara E, Taguchi Y, Dougu N, Nozawa T, Tanaka K, Inoue H.

Am J Cardiol. 2011 Mar 15;107(6):912-6. doi: 10.1016/j.amjcard.2010.10.074. Epub 2011 Jan 19.

PMID:
21247518
16.

Validation of contemporary stroke and bleeding risk stratification scores in non-anticoagulated Chinese patients with atrial fibrillation.

Guo Y, Apostolakis S, Blann AD, Wang H, Zhao X, Zhang Y, Zhang D, Ma J, Wang Y, Lip GY.

Int J Cardiol. 2013 Sep 30;168(2):904-9. doi: 10.1016/j.ijcard.2012.10.052. Epub 2012 Nov 17.

PMID:
23167998
17.

Renal dysfunction and the risk of thromboembolic events in patients with atrial fibrillation after catheter ablation--the potential role beyond the CHA₂DS₂-VASc score.

Chao TF, Tsao HM, Ambrose K, Lin YJ, Lin WS, Chang SL, Lo LW, Hu YF, Tuan TC, Suenari K, Li CH, Hartono B, Chang HY, Chung FP, Hanafy DA, Lin WY, Chen SA.

Heart Rhythm. 2012 Nov;9(11):1755-60. doi: 10.1016/j.hrthm.2012.06.039. Epub 2012 Jun 30.

PMID:
22760084
18.

A new risk scheme to predict ischemic stroke and other thromboembolism in atrial fibrillation: the ATRIA study stroke risk score.

Singer DE, Chang Y, Borowsky LH, Fang MC, Pomernacki NK, Udaltsova N, Reynolds K, Go AS.

J Am Heart Assoc. 2013 Jun 21;2(3):e000250. doi: 10.1161/JAHA.113.000250.

19.

Renal impairment in a "real-life" cohort of anticoagulated patients with atrial fibrillation (implications for thromboembolism and bleeding).

Roldán V, Marín F, Fernández H, Manzano-Fernández S, Gallego P, Valdés M, Vicente V, Lip GY.

Am J Cardiol. 2013 Apr 15;111(8):1159-64. doi: 10.1016/j.amjcard.2012.12.045. Epub 2013 Jan 18.

PMID:
23337836
20.

Does CHA2DS2-VASc improve stroke risk stratification in postmenopausal women with atrial fibrillation?

Abraham JM, Larson J, Chung MK, Curtis AB, Lakshminarayan K, Newman JD, Perez M, Rexrode K, Shara NM, Solomon AJ, Stefanick ML, Torner JC, Wilkoff BL, Wassertheil-Smoller S.

Am J Med. 2013 Dec;126(12):1143.e1-8. doi: 10.1016/j.amjmed.2013.05.023. Epub 2013 Oct 17.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk